Cargando…

International Guidelines for the Treatment of Huntington's Disease

The European Huntington's Disease Network (EHDN) commissioned an international task force to provide global evidence-based recommendations for everyday clinical practice for treatment of Huntington's disease (HD). The objectives of such guidelines are to standardize pharmacological, surgic...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bachoud-Lévi, Anne-Catherine, Ferreira, Joaquim, Massart, Renaud, Youssov, Katia, Rosser, Anne, Busse, Monica, Craufurd, David, Reilmann, Ralf, De Michele, Giuseppe, Rae, Daniela, Squitieri, Ferdinando, Seppi, Klaus, Perrine, Charles, Scherer-Gagou, Clarisse, Audrey, Olivier, Verny, Christophe, Burgunder, Jean-Marc
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2019
Materias:	Neurology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6618900/ https://www.ncbi.nlm.nih.gov/pubmed/31333565 http://dx.doi.org/10.3389/fneur.2019.00710

Ejemplares similares

Cognitive decline in Huntington’s disease in the Digitalized Arithmetic Task (DAT)
por: Lunven, Marine, et al.
Publicado: (2021)

A new approach to digitized cognitive monitoring: validity of the SelfCog in Huntington’s disease
por: Lunven, Marine, et al.
Publicado: (2023)

Cognitive processes of apathy in Huntington’s disease show high sensitivity to disease progression
por: Hare, Emily, et al.
Publicado: (2022)

Cell therapy in Huntington's disease: Taking stock of past studies to move the field forward
por: Bachoud‐Lévi, Anne‐Catherine, et al.
Publicado: (2020)

Objectively characterizing Huntington’s disease using a novel upper limb dexterity test
por: Woodgate, Samuel, et al.
Publicado: (2021)

Self-Reported Social Relationship Capacities Predict Motor, Functional and Cognitive Decline in Huntington’s Disease
por: Lemercier, Pablo, et al.
Publicado: (2022)

How to Capitalize on the Retest Effect in Future Trials on Huntington’s Disease
por: Schramm, Catherine, et al.
Publicado: (2015)

Combining Literature Review With a Ground Truth Approach for Diagnosing Huntington's Disease Phenocopy
por: Nguyen, Quang Tuan Rémy, et al.
Publicado: (2022)

Corrigendum: Combining Literature Review With a Ground Truth Approach for Diagnosing Huntington's Disease Phenocopy
por: Nguyen, Quang Tuan Rémy, et al.
Publicado: (2022)

Insulin-Like Growth Factor-1 but Not Insulin Predicts Cognitive Decline in Huntington’s Disease
por: Salem, Linda, et al.
Publicado: (2016)

Effectiveness of Anti-Psychotics and Related Drugs in the Huntington French-Speaking Group Cohort
por: Désaméricq, Gaëlle, et al.
Publicado: (2014)

COMT Val(158)Met Polymorphism Modulates Huntington's Disease Progression
por: de Diego-Balaguer, Ruth, et al.
Publicado: (2016)

Predicting clinical scores in Huntington’s disease: a lightweight speech test
por: Riad, Rachid, et al.
Publicado: (2022)

Progression of motor subtypes in Huntington’s disease: a 6-year follow-up study
por: Jacobs, M., et al.
Publicado: (2016)

Symptomatic treatment options for Huntington’s disease (guidelines of the German Neurological Society)
por: Saft, Carsten, et al.
Publicado: (2023)

Neocortical morphometry in Huntington's disease: Indication of the coexistence of abnormal neurodevelopmental and neurodegenerative processes
por: Mangin, Jean-Francois, et al.
Publicado: (2020)

Longitudinal Study of Informed Consent in Innovative Therapy Research: Experience and Provisional Recommendations from a Multicenter Trial of Intracerebral Grafting
por: Cleret de Langavant, Laurent, et al.
Publicado: (2015)

Genetic Counseling in Huntington's Disease: Potential New Challenges on Horizon?
por: Migliore, Simone, et al.
Publicado: (2019)

Awareness of Memory Deficits in Early Stage Huntington's Disease
por: Cleret de Langavant, Laurent, et al.
Publicado: (2013)

Profile of pridopidine and its potential in the treatment of Huntington disease: the evidence to date
por: Squitieri, Ferdinando, et al.
Publicado: (2015)

Different depression: motivational anhedonia governs antidepressant efficacy in Huntington’s disease
por: McLauchlan, Duncan James, et al.
Publicado: (2022)

Neuroendocrine Disturbances in Huntington's Disease
por: Saleh, Nadine, et al.
Publicado: (2009)

The specific role of the striatum in interval timing: The Huntington’s disease model
por: Lemoine, Laurie, et al.
Publicado: (2021)

Respiratory decline is integral to disease progression in Huntington's disease
por: Jones, Una, et al.
Publicado: (2016)

The Impact of Upcoming Treatments in Huntington’s Disease: Resource Capacity Limitations and Access to Care Implications
por: Guttman, Mark, et al.
Publicado: (2021)

Assessment of Depression, Anxiety and Apathy in Prodromal and Early Huntington Disease
por: Vaccarino, Anthony L, et al.
Publicado: (2011)

Safer Attitude to Risky Decision-Making in Premanifest Huntington’s Disease Subjects
por: D’Aurizio, Giulia, et al.
Publicado: (2019)

Sleep Quality and Related Clinical Manifestations in Huntington Disease
por: Maffi, Sabrina, et al.
Publicado: (2022)

Alloimmunisation to Donor Antigens and Immune Rejection Following Foetal Neural Grafts to the Brain in Patients with Huntington's Disease
por: Krystkowiak, Pierre, et al.
Publicado: (2007)

Deep White Matter in Huntington's Disease
por: Phillips, Owen, et al.
Publicado: (2014)

DNA instability in replicating Huntington's disease lymphoblasts
por: Cannella, Milena, et al.
Publicado: (2009)

Current Diagnostic Methods and Non-Coding RNAs as Possible Biomarkers in Huntington’s Disease
por: Pellegrini, Miguel, et al.
Publicado: (2022)

Translational research in Huntington’s disease: opening up for disease modifying treatment
por: Burgunder, Jean-Marc
Publicado: (2013)

Tractography of the Corpus Callosum in Huntington’s Disease
por: Phillips, Owen, et al.
Publicado: (2013)

Aripiprazole in the treatment of Huntington’s disease: a case series
por: Ciammola, Andrea, et al.
Publicado: (2009)

Pharmacological treatment of chorea in Huntington’s disease–good clinical practice versus evidence-based guideline
por: Reilmann, Ralf
Publicado: (2013)

Current Pharmacological Management in Juvenile Huntington’s Disease
por: Robertson, Lisa, et al.
Publicado: (2012)

Brain-Derived Neurotrophic Factor in Patients with Huntington's Disease
por: Zuccato, Chiara, et al.
Publicado: (2011)

Nitric Oxide Dysregulation in Platelets from Patients with Advanced Huntington Disease
por: Carrizzo, Albino, et al.
Publicado: (2014)

Emotion recognition and inhibitory control in manifest and pre-manifest Huntington's disease: evidence from a new Stroop task
por: Hünefeldt, Thomas, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_qp3p8liu5bk9cfd5u5uoiimjkg